









Markets
/
Stocks
/
nasdaq-alvo
/

Alvotech SA

ALVO

7.880USD

+0.060+0.77%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

2.46BMarket Cap

38.75P/E TTM



Alvotech SA

7.880

+0.060+0.77%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

111 / 506

Overall Ranking

214 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

17.500

Target Price

+123.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 478.68% year-on-year.

Overvalued

The company’s latest PE is 32.71, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 212.13M shares, decreasing 2.07% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.23M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.47.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.32, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 173.34M, representing a year-over-year decrease of 12.79%, while its net profit experienced a year-over-year decrease of 50.88%.

Score

Industry at a Glance

Previous score

8.32

Change



Financials

4.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 32.46, which is -110.02% below the recent high of -3.25 and 119.11% above the recent low of -6.20.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 111/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Alvotech SA is 14.00, with a high of 28.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

17.500

Target Price

+123.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Alvotech SA

ALVO

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.90, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 8.33 and the support level at 7.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.90

Change

0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.009

Neutral

RSI(14)

40.759

Neutral

STOCH(KDJ)(9,3,3)

23.661

Neutral

ATR(14)

0.207

Low Volatility

CCI(14)

-109.715

Sell

Williams %R

80.303

Oversold

TRIX(12,20)

-0.299

Sell

StochRSI(14)

30.669

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

7.942

Sell

MA10

8.009

Sell

MA20

8.070

Sell

MA50

8.496

Sell

MA100

9.074

Sell

MA200

10.247

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 69.90%, representing a quarter-over-quarter decrease of 0.23%. The largest institutional shareholder is The Vanguard, holding a total of 4.23M shares, representing 1.36% of shares outstanding, with 28.27% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Aztiq Pharma Partners SARL

101.15M

-2.49%

Celtic Holdings SCA

90.01M

The Vanguard Group, Inc.

Star Investors

4.19M

+31.14%

Bracebridge Capital, LLC

2.71M

Oaktree Capital Management, L.P.

Star Investors

1.97M

-3.35%

T. Rowe Price International Ltd

1.40M

+587.57%

Littlejohn & Co. LLC

1.32M

Davies (Richard John)

1.07M

+1.88%

PointState Capital LP

1.17M

-5.40%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.07, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.10. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.